Rona Therapeutics enters into global license agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases

Summary

Rona Therapeutics has entered into a global license agreement with Roche for an ALK7-targeting RNAi therapy targeting obesity and metabolic diseases. This strategic partnership represents a significant collaboration for advancing therapeutic options in the metabolic disease space.